Pharmacologic surveillance and safety evaluation of new drugs.
DOI:
https://doi.org/10.20344/amp.3341Abstract
Efficacy and safety evaluation are the main objectives of clinical trials. Through a rigorous scientific methodology they compare the efficacy of the new drugs with that of standard drugs or placebo. However the design of clinical trials in phase III is more centered in the study of efficacy than in its safety. Other reason, apart this, is a natural consequence of the low number of patients recruited for this phase when the incidence of most type B adverse drug reactions is usually of the order of 1:10(-4). Therefore it is the author's contention that post-marketing (phase IV) trials and surveillance should become commoner practices since they can contribute for a permanent evaluation of drugs safety after their approval and introduction in the market.Downloads
Downloads
How to Cite
Issue
Section
License
All the articles published in the AMP are open access and comply with the requirements of funding agencies or academic institutions. The AMP is governed by the terms of the Creative Commons ‘Attribution – Non-Commercial Use - (CC-BY-NC)’ license, regarding the use by third parties.
It is the author’s responsibility to obtain approval for the reproduction of figures, tables, etc. from other publications.
Upon acceptance of an article for publication, the authors will be asked to complete the ICMJE “Copyright Liability and Copyright Sharing Statement “(http://www.actamedicaportuguesa.com/info/AMP-NormasPublicacao.pdf) and the “Declaration of Potential Conflicts of Interest” (http:// www.icmje.org/conflicts-of-interest). An e-mail will be sent to the corresponding author to acknowledge receipt of the manuscript.
After publication, the authors are authorised to make their articles available in repositories of their institutions of origin, as long as they always mention where they were published and according to the Creative Commons license.
